<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955240</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642638</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-16-0708</secondary_id>
    <secondary_id>EU-20941</secondary_id>
    <secondary_id>2007-007029-38</secondary_id>
    <nct_id>NCT00955240</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer</brief_title>
  <official_title>Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal&#xD;
      antibodies, such as cetuximab, can block tumor growth in different ways. Some block the&#xD;
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or&#xD;
      carry tumor-killing substances to them. Giving radiation therapy together with combination&#xD;
      chemotherapy and cetuximab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving radiation therapy together with cisplatin,&#xD;
      fluorouracil, and cetuximab to see how well it works in treating patients with locally&#xD;
      advanced anal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the objective response (complete and partial) 8 weeks after completion of study&#xD;
           treatment comprising radiotherapy, chemotherapy (fluorouracil and cisplatin), and&#xD;
           cetuximab followed by additional radiotherapy in patients with locally advanced anal&#xD;
           cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate colostomy-free survival.&#xD;
&#xD;
        -  Evaluate the local control rate (objective response and stabilization) at 8 weeks.&#xD;
&#xD;
        -  Evaluate relapse-free survival at 5 years.&#xD;
&#xD;
        -  Evaluate the intermediate objective response at the end of week 5 of radiotherapy.&#xD;
&#xD;
        -  Evaluate overall survival at 5 years.&#xD;
&#xD;
        -  Evaluate the duration of response.&#xD;
&#xD;
        -  Evaluate acute toxicities according to CTCAE v3.0.&#xD;
&#xD;
        -  Evaluate late toxicities at 5 years according to CTCAE v3.0.&#xD;
&#xD;
        -  Study the tumor markers associated with response (survival without relapse) and&#xD;
           toxicity.&#xD;
&#xD;
        -  Study the genotypes of Fc-receptor immunoglobulins (FCGR2A and FCGR3) and their&#xD;
           association with skin toxicity, objective survival, and relapse-free survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cetuximab IV on days 0, 7, 14, 21, 28, and 35; fluorouracil IV on days 7-10&#xD;
      and 35-38; and cisplatin IV over 2 hours on days 7 and 35. Beginning on day 7, patients also&#xD;
      undergo radiotherapy 5 days a week for 5 weeks (weeks 2-6). Two weeks after finishing this&#xD;
      treatment, patients undergo additional radiotherapy* 5 days a week for 2 weeks (weeks 9 and&#xD;
      10).&#xD;
&#xD;
      NOTE: *Some patients may undergo brachytherapy.&#xD;
&#xD;
      Blood and tissue samples are collected for further analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate toxicity&#xD;
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 26, 2010</completion_date>
  <primary_completion_date type="Actual">November 26, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate at 3 and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colostomy-free survival at 3 and 5 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Anal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed anal cancer&#xD;
&#xD;
               -  Squamous cell disease&#xD;
&#xD;
               -  Locally advanced, non-metastatic disease&#xD;
&#xD;
               -  One of the following clinical TNM stages:&#xD;
&#xD;
                    -  T2, N0, M0 (largest diameter ≥ 3 cm)&#xD;
&#xD;
                    -  T3-T4, N0, M0&#xD;
&#xD;
                    -  Any T, N1-N3, M0&#xD;
&#xD;
          -  No undifferentiated small cell carcinoma or adenocarcinoma&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  Undergone endorectal ultrasound or MRI to evaluate the primary tumor&#xD;
&#xD;
          -  Undergone thoraco-abdomino-pelvic scan to evaluate tumor extension&#xD;
&#xD;
          -  Disease suitable to receive radiotherapy and chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Leukocytes ≥ 4,000/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  ALT and AST ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No history of cancer within the past 8 years except for in situ cervical cancer or&#xD;
             previously treated basal cell carcinoma of the skin&#xD;
&#xD;
          -  No contraindications to any component of study therapy&#xD;
&#xD;
          -  No serious uncontrolled illness&#xD;
&#xD;
          -  No symptomatic grade 1 angina pectoris or angina pectoris ≥ grade 2&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No peripheral sensory neuropathy&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No geographical, social, or psychological situations that preclude medical follow up&#xD;
&#xD;
          -  Affiliated with a social security system&#xD;
&#xD;
          -  No patient deprived of liberty or under trusteeship&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Patients with a diverting colostomy are eligible&#xD;
&#xD;
          -  No prior excision of this tumor&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for the treatment of this cancer or any other&#xD;
             history of radiotherapy or pelvic brachytherapy&#xD;
&#xD;
          -  No concurrent coumarin anticoagulants, phenytoin, sorivudine or brivudine, antacids,&#xD;
             or allopurinol&#xD;
&#xD;
          -  Not registered in another clinical trial with an experimental drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Deutsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Prive Saint-Gregoire</name>
      <address>
        <city>Saint-Gregoire</city>
        <zip>35768</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad Garonne</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II anal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>squamous cell carcinoma of the anus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

